Recommended Pages at newsroom.lilly.com
Eli Lilly and Company - BYETTA® Approved for Use with Basal Insulin in Europe
newsroom.lilly.com — “Eli Lilly and Company - BYETTA® Approved for Use with Basal Insulin in Europe” View full resource at newsroom.lilly.com
Most Recently Shared on March 23, 2012 at 6:43 pm By:
BYETTA® Approved for Use with Basal Insulin in Europe (Lilly) http://t.co/W8GNvepK
Eli Lilly and Company - Lilly and Amylin Mutually Agree to End Diabetes Alliance and Transition Exenatide Responsibility to Amylin
newsroom.lilly.com — “Eli Lilly and Company - Lilly and Amylin Mutually Agree to End Diabetes Alliance and Transition Exenatide Responsibility to Amylin” View full resource at newsroom.lilly.com
Most Recently Shared on November 8, 2011 at 2:12 pm By:
eyeonfda Pharma and Health Lawyer
Lilly & Amylin Mutually Agree to End Diabetes Alliance; Transition Exenatide Responsibility to Amylin http://t.co/XoJPyuM8 #diabetes
Eli Lilly and Company - Linagliptin Receives Approval in Europe for the Treatment of Type 2 Diabetes
newsroom.lilly.com — “Eli Lilly and Company - Linagliptin Receives Approval in Europe for the Treatment of Type 2 Diabetes” View full resource at newsroom.lilly.com
Most Recently Shared on August 26, 2011 at 6:11 pm By:
Linagliptin only DPP-4 inhibitor approved at one dosage strength for adults with type 2 diabetes in Europe (Lilly) http://t.co/03eAQFp
Eli Lilly and Company - BYDUREON™ FDA ACTION DATE SET FOR JANUARY 28, 2012
newsroom.lilly.com — “Eli Lilly and Company - BYDUREON™ FDA ACTION DATE SET FOR JANUARY 28, 2012” View full resource at newsroom.lilly.com
Most Recently Shared on August 11, 2011 at 6:16 pm By:
Bydureon™ FDA action date set for January 28, 2012 (Lilly) http://bit.ly/qVDZ4i
Eli Lilly and Company - Exenatide tQT Study Showed No Prolongation of QT Interval
newsroom.lilly.com — “Eli Lilly and Company - Exenatide tQT Study Showed No Prolongation of QT Interval” View full resource at newsroom.lilly.com
Most Recently Shared on July 8, 2011 at 6:19 pm By:
Exenatide tQT Study Showed No Prolongation of QT Interval (lilly) http://bit.ly/p2xaDV
Eli Lilly and Company - Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations
newsroom.lilly.com — “Eli Lilly and Company - Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations” View full resource at newsroom.lilly.com
Most Recently Shared on June 30, 2011 at 12:05 pm By:
Lisa Jarvis Science Enthusiast
$LLY outlines strategy for investors, expects 10 NMEs in PIII by end of yr: http://t.co/nS7R0IY
Eli Lilly and Company - FDA Approves Updates to Lilly's Humalog® (insulin lispro injection [rDNA origin]) Label
newsroom.lilly.com — “Eli Lilly and Company - FDA Approves Updates to Lilly's Humalog® (insulin lispro injection [rDNA origin]) Label” View full resource at newsroom.lilly.com
Most Recently Shared on June 8, 2011 at 10:31 pm By:
FDA Approves Updates to Lilly's Humalog® (insulin lispro injection [rDNA origin]) Label http://bit.ly/jZ4a7v
Eli Lilly and Company - Lilly Comments on Court Ruling in Amylin Litigation
newsroom.lilly.com — “Eli Lilly and Company - Lilly Comments on Court Ruling in Amylin Litigation” View full resource at newsroom.lilly.com
Most Recently Shared on May 26, 2011 at 4:05 pm By:
Lilly Comments on Court Ruling in Amylin Litigation http://bit.ly/j1redd
Eli Lilly and Company - FDA Approves Tradjenta™ (linagliptin) Tablets for the Treatment of Type 2 Diabetes
newsroom.lilly.com — “Eli Lilly and Company - FDA Approves Tradjenta™ (linagliptin) Tablets for the Treatment of Type 2 Diabetes” View full resource at newsroom.lilly.com
Most Recently Shared on May 2, 2011 at 10:51 pm By:
Hope Warshaw Nutritionist and Dietitian
Looks like FDA approved Lilly/Boehringer Ingelheim's DPP-4 linagliptin/Tradjenta today 5/2. Read Lilly press release: http://bit.ly/jtGvcz
Eli Lilly and Company - BYDUREON™ Recommended for Approval in Europe
newsroom.lilly.com — “Eli Lilly and Company - BYDUREON™ Recommended for Approval in Europe” View full resource at newsroom.lilly.com
Most Recently Shared on April 15, 2011 at 5:19 pm By:
BYDUREONâ„¢ Recommended for Approval in Europe (Lilly) http://bit.ly/hKbd0S
Eli Lilly and Company - DURATION-6 Top-Line Study Results Announced
newsroom.lilly.com — “Eli Lilly and Company - DURATION-6 Top-Line Study Results Announced” View full resource at newsroom.lilly.com
Most Recently Shared on March 4, 2011 at 8:29 am By:
DURATION-6 Top-Line Study Results Announced (Lilly) http://bit.ly/gir62V
Eli Lilly and Company - Lilly and the Juvenile Diabetes Research Foundation Partner to Fund Regenerative Medicine Research in Type 1 Diabetes
newsroom.lilly.com — “Eli Lilly and Company - Lilly and the Juvenile Diabetes Research Foundation Partner to Fund Regenerative Medicine Research in Type 1 Diabetes” View full resource at newsroom.lilly.com
Most Recently Shared on February 3, 2011 at 9:12 pm By:
Lilly and the Juvenile Diabetes Research Foundation Partner to Fund Regenerative Medicine Research in Type 1 Diabetes http://bit.ly/gKkhk5
Eli Lilly and Company - Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab
newsroom.lilly.com — “Eli Lilly and Company - Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab” View full resource at newsroom.lilly.com
Most Recently Shared on February 2, 2011 at 2:55 pm By:
RT @MaverickNYLilly & BMS halt phase III lung cancer trials w/ an IGF-1R monoclonal due to blood clots http://bit.ly/gmbhzw $LLY $BMY
Eli Lilly and Company - President of Lilly Oncology Announces Resignation
newsroom.lilly.com — “Eli Lilly and Company - President of Lilly Oncology Announces Resignation” View full resource at newsroom.lilly.com
Most Recently Shared on January 25, 2011 at 3:17 pm By:
eyeonfda Pharma and Health Lawyer
President of Lilly Oncology Announces Resignation - http://ow.ly/3JRGq
Eli Lilly and Company - Lilly and Boehringer Ingelheim Announce Strategic Alliance to Bring New Diabetes Treatments to Patients Worldwide
newsroom.lilly.com — “Eli Lilly and Company - Lilly and Boehringer Ingelheim Announce Strategic Alliance to Bring New Diabetes Treatments to Patients Worldwide” View full resource at newsroom.lilly.com
Most Recently Shared on January 11, 2011 at 2:22 pm By:
eyeonfda Pharma and Health Lawyer
Lilly and Boehringer Ingelheim Announce Strategic Alliance to Bring New #Diabetes Treatments - http://ow.ly/3BNpG
